NeXtGen Biologics key facts
as of Oct 2026- Developer of extracellular matrix biomaterial products designed to harness axolotl-derived extracellular matrix components for tissue regeneration.
- NeXtGen Biologics is valued at approximately $6.6M as of Oct 2026 (last reported valuation).
- It has raised $6.7M across 2 recorded rounds; the latest was Seed Round ($2.2M) in Dec 2018.
- Notable investors include Brian Lipke, Elad Levy, Gerald Lippes, Jerry Jacobs, Mark Hamister — 8 tracked in total.
- NeXtGen Biologics has filed 7 Form Ds with the SEC since 2014, most recently Sep 2025 ($130K sold to 3 investors).
- Status: Privately Held (backing).
NeXtGen Biologics's last reported valuation, Nov 2015. Nothing priced has surfaced since.
- ·Watch NeXtGen Biologics: the Monday email on marks, rounds and moves
NeXtGen Biologics funding rounds
2 roundsWho backs NeXtGen Biologics
8NeXtGen Biologics valuation
NeXtGen Biologics's last reported valuation was $6.6 million in Nov 2015. No priced round, secondary trade or fund mark has surfaced since.
How much has NeXtGen Biologics raised?
NeXtGen Biologics has raised $6.7 million in total; 2 of its rounds are on record. The largest on record was a $500,000 debt round in Aug 2014; the most recent was a $2.2 million seed round in Dec 2018.
NeXtGen Biologics has filed 7 Form Ds with the SEC since 2014, most recently in Sep 2025 ($130,000 sold to 3 investors).
NeXtGen Biologics investors
8 investors are on record for NeXtGen Biologics, including Brian Lipke, Elad Levy, Gerald Lippes and Jerry Jacobs. The seed round in Dec 2018 drew 19 investors.
About NeXtGen Biologics
Developer of extracellular matrix biomaterial products designed to harness axolotl-derived extracellular matrix components for tissue regeneration. The company offers a collagen wound matrix sourced from the axolotl's extracellular matrix to better manage complex conditions seen in general surgery, trauma, cardiovascular diseases, neurosurgery, orthopedics, and ophthalmology, enabling clinicians treating partial and full-thickness wounds to support healing and improve the wound environment.
- Sector
- Healthcare
- HQ
- Alachua, FL, United States
- Founded
- 2014
- Employees
- 7
- Website
- nextgenbiologics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.